Intravitreal bevacizumab in a patient with a macular star in malignant hypertension.

Abstract

PURPOSE:

To report a case of retinopathy secondary to malignant hypertension showing a macular star, which responded favorably to a single intravitreal injection of bevacizumab (IVB).

METHODS:

A 46-year-old man with malignant hypertension showing incomplete macular star in his right eye with best-corrected visual acuity (BCVA) of 20/32 underwent IVB.

RESULTS:

Subsequent examinations revealed a progressive resolution of the macular star with functional recovery over the follow-up. In particular, at the 9-month examination BCVA was 20/20, fundus biomicroscopy disclosed resolution of the macular star, and the retinal sensitivity improved remarkably.

CONCLUSIONS:

Intravitreal injection of bevacizumab can be a useful approach to treat the exudative manifestations of malignant hypertension.

• Authors: Ilaria Zucchiatti, Pierluigi Iacono, Maurizio Battaglia Parodi, Maria Lucia Cascavilla, Dimitris Stelios Kontadakis, Francesco Bandello
• Journal: European journal of ophthalmology (Eur J Ophthalmol) 2011 May-Jun Vol. 21 Issue 3 Pg. 336-9 ISSN: 1724-6016 [Electronic] United States
• PMID: 20954147 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Angiogenesis Inhibitors (administration & dosage, therapeutic use)
• Antibodies, Monoclonal (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Blood Pressure (physiology)
• Fluorescein Angiography
• Humans
• Hypertension, Malignant (complications)
• Intravitreal Injections
• Male
• Middle Aged
• Retinal Diseases (diagnosis, drug therapy, etiology)
• Tomography, Optical Coherence
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity (physiology)